Arterial thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis

Journal of the National Cancer Institute

Volumn 104, Issue 23, 2012, Pages 1837-1840

  Proverbs Singh, Tracy ^a   Chiu, Sophia K ^a   Liu, Ziyue ^b   Seng, Sonia ^d   Sonpavde, Guru ^e   Choueiri, Toni K ^f   Tsao, Che Kai ^a   Yu, Menggang ^g   Hahn, Noah M ^c   Oh, William K ^a   Galsky, Matthew D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Biostatistics ^*  (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Southcoast Centers for Cancer Care   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ARTERIAL THROMBOEMBOLISM; CANCER CHEMOTHERAPY; CONFIDENCE INTERVAL; DRUG DOSE REGIMEN; DRUG SAFETY; HUMAN; INCIDENCE; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; SYSTEMATIC REVIEW;

EID: 84870918725     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs435     Document Type: Review

References (14)

1. Khorana AA, Francis CW, Culakova E, et al Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634.
2. Seng S, Liu Z, Chiu S., et al Risk of venous thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Clin Oncol. In press.
3. Doll DC, List A F, Greco FA, et al Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105(1):48-51.
4. Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs. 2008;19(9):927-929.
5. Jadad AR, Moore RA, Carroll D, et al Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
6. Viechtbauer W. Conducting meta-analysis in R with the metafor package. J Stat Soft w. 2010;36(3):1-48.
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
8. Deeks JJ, Altman DG, Bradburn MJ Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. London: BMJ Books; 2011.
9. Hedges LV, Pigott TD The power of statistical tests in meta-analysis. Psychol Methods. 2001;6(3):203-217.
10. Moore RA, Adel N, Riedel E., et al High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011; 29(25):3466-3473.
11. Numico G, Garrone O, Dongiovanni V., et al Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103(5):994-999.
12. Anders JC, Grigsby PW, Singh AK Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature. Radiat Oncol. 2006;1:14.
13. Reynolds MW, Shibata A, Zhao S., et al Impact of clinical trial design and execution-related factors on incidence of thromboem-bolic events in cancer patients: a systematic review and meta-analysis. Curr Med Res Opin. 2008;24(2):497-505.
14. Bradburn MJ, Deeks JJ, Berlin J.A., et al Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1):53-77.